luxgen genome center
The LuxGen Platform provides a full range of expert support services in sample preparation, microarray analysis, RNA-sequencing, biostatistics and bioinformatics.
activities
As a collaboration between LIH and LNS, the main goal of the Center is to contribute to the partners’ respective and common translational transversal medicine research efforts and to provide sequencing capacity to internal and third party users.
The Center can be used as a service by either party, individually or jointly, or by a third party.
The Center is operated by a team composed of members from both partner organisations and led by an Operational Head of the Center, who will report to the LuxGen Steering Body.
Featured team members
-
Pol
Hoffmann Laboratory Technician -
Barbara
Klink Group Leader -
Arnaud
Muller Bioinformatician -
Nathalie
Nicot Research Engineer
Barbara
Klink
Klink
Scientific publications
-
Extracellular vesicle derived-MIR-146A increases melanoma brain metastasis progression via notch signalling pathway dysregulation – 05/09/2022
-
Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson’s disease – 29/01/2022
-
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia – 01/01/2021
-
PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα – 25/06/2021
-
A New Synuclein-Transgenic Mouse Model for Early Parkinson’s Reveals Molecular Features of Preclinical Disease – 01/02/2021
-
Systematic Transcriptional Profiling of Responses to STAT1- and STAT3-Activating Cytokines in Different Cancer Types – 06/11/2020
-
Extracellular atp and cd39 activate camp-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia – 01/01/2020
-
Tumor suppressor miR-215 counteracts hypoxia-induced colon cancer stem cell activity – 28/05/2019
-
The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies – 01/11/2018
-
RNA sequencing and transcriptome arrays analyses show opposing results for alternative splicing in patient derived samples – 06/06/2017
